CD38 and Miyoshi myopathy: A Flatiron Health Database study revealed that lenalidomide‐based regimens are the most commonly used treatment option in patients with MM, as monotherapy or combination therapy (with PI or anti‐CD38 mAB), despite experiencing relapse on lenalidomide.22